Elisabeth Gaye is an expert in Oncology at Centre Oscar Lambret (France). Elisabeth Gaye has authored 13 publications, the most recent in 2024, and is an investigator in 1 clinical trial. SLR score: 53 (community average: 125). How the SLR is computed.

LeadR Profile

Elisabeth Gaye Centre Oscar Lambret France
53 ScienceLeadR Reputation 53
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2017 - 2024

Source: PubMed

Centre Oscar Lambret

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 13

Citations

Citations: 96 1st author: 4 Last author: 1 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O 6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).
PMID 39586038 — methyltransferases, o(6)-methylguanine-dna methyltransferase, neoplasms, alkylating agents, drug therapy, oxaliplatin, neuroendocrine tumors, chemotherapy
J Clin Oncol Top journal202411
Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
PMID 35943440 — genes, epidermal growth factor, growth, breast neoplasms, pharmaceutical preparations, esophagogastric junction, neoplasms, carcinoma, non-small-cell lung, breast, therapeutics
Curr Opin Oncol20228
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
PMID 32412157 — carcinoma, non-small-cell lung, immunotherapy, cells, lung neoplasms, small cell lung carcinoma, disease-free survival, nivolumab, progression-free survival
Cancer Med20204
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
PMID 31484705 — ligands, cells, therapeutics, stomach neoplasms, cell line, trastuzumab
Mol Cancer Ther201945
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
PMID 31200813 — brain, neoplasm metastasis, carcinoma, non-small-cell lung, cells, lung neoplasms, small cell lung carcinoma, meningeal carcinomatosis
Lung Cancer201921

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map